Therapeutic effects of crizotinib in EML4-ALK-positive patients with non-small-cell lung cancer.
- Author:
Xuan WU
1
;
Jianxiong LI
Author Information
- Publication Type:Clinical Trial
- MeSH: Carcinoma, Non-Small-Cell Lung; drug therapy; Disease-Free Survival; Humans; Lung Neoplasms; drug therapy; Oncogene Proteins, Fusion; Pyrazoles; administration & dosage; therapeutic use; Pyridines; administration & dosage; therapeutic use
- From: Journal of Southern Medical University 2015;35(5):753-757
- CountryChina
- Language:Chinese
-
Abstract:
OBJEVTIVETo evaluate the therapeutic effects of different therapeutic regimens for non-small-cell lung cancer (NSCLC) with or without EML4-ALK rearrangement.
METHODSTwenty-one ALK-positive and 50 ALK-negative NSCLC patients who received voluntarily EML4-ALK testing and 75 NSCLC patients without AL testing were enrolled in this study. The 3 groups of patients received different treatments, and the therapeutic effects, progression-free survival (PFS), and treatment-related adverse events were analyzed.
RESULTSCrizotinib treatment obviously prolonged the PFS in EML4-ALK-positive patients with an objective response rate (OOR) of 61.9% and a median response duration of 16 months, which were significantly better than those in with ALK-negative patients and patients without ALK testing who received different second-line therapies.
CONCLUSIONCrizotinib is superior to platinum-based chemotherapy in NSCLC patients with ALK rearrangement. ALK rearrangement id not a modifier of the effect of chemotherapy regimens in NSCLC patients.
